Abram, Samantha V.
Roach, Brian J.
Fryer, Susanna L.
Calhoun, Vince D.
Preda, Adrian
van Erp, Theo G. M.
Bustillo, Juan R. http://orcid.org/0000-0001-8730-8152
Lim, Kelvin O. http://orcid.org/0000-0002-2390-7268
Loewy, Rachel L.
Stuart, Barbara K.
Krystal, John H. http://orcid.org/0000-0001-6952-1726
Ford, Judith M. http://orcid.org/0000-0002-6500-6548
Mathalon, Daniel H. http://orcid.org/0000-0001-6090-4974
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (NIH 1 U24 RR021992, NIH 1 U24 RR025736-01, NIH 1 U24 RR025736-01, NIH 1 U24 RR021992, NIH 1 U24 RR025736-01, NIH 1 U24 RR021992, NIH 1 U24 RR025736-01, NIH 1 U24 RR021992, NIH 1 U24 RR025736-01, NIH 1 U24 RR021992, NIH 1 U24 RR025736-01, NIH 1 U24 RR021992, NIH 1 U24 RR025736-01)
U.S. Department of Health & Human Services | National Institutes of Health
North Carolina GlaxoSmithKline Foundation
U.S. Department of Veterans Affairs
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01 MH076989)
MIRECC Advanced Schizophrenia Fellowship
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (NIH 1 U24 RR021992)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 26 June 2021
Revised: 7 February 2022
Accepted: 22 February 2022
First Online: 14 April 2022
Competing interests
: DHM consults for Boehringer Ingelheim International, Cadent Therapeutics, Syndesi Therapeutics, Recognify Life Sciences, and Gilgamesh Pharmaceuticals. JHK consults for AstraZeneca Pharmaceuticals, Biogen Idec, Biomedisyn, Bionomics Ltd., Boehringer Ingelheim International, COMPASS Pathways Ltd., Concert Pharmaceuticals, Inc., Epiodyne, Inc., EpiVario, Inc., Heptares Therapeutics Ltd., Janssen Research & Development, Otsuka America Pharmaceutical, Inc., Perception Neuroscience Holdings, Inc., Spring Care, Inc., Sunovion Pharmaceuticals, Inc., Takeda Industries, and Taisho Pharmaceutical Co., Ltd.; is a scientific advisor of Bioasis Technologies, Inc., Biohaven Pharmaceuticals, BioXcel Therapeutics, Inc. (Clinical Advisory Board), BlackThorn Therapeutics, Inc., Cadent Therapeutics (Clinical Advisory Board), Cerevel Therapeutics, LLC, EpiVario, Inc., Lohocla Research Corporation, Novartis Pharmaceuticals Corporation, and PsychoGenics, Inc.; is a member of the board of directors of Inheris Biopharma, Inc.; holds stock or stock options with Biohaven Pharmaceuticals, Sage Pharmaceuticals, Spring Care, Inc., BlackThorn Therapeutics, Inc., EpiVario, Inc., and Terra Life Sciences; and is editor of <i>Biological Psychiatry</i>. JHK was also awarded the following patents: (i) Seibyl JP, Krystal JH, Charney DS. Dopamine and Noradrenergic Reuptake Inhibitors in Treatment of Schizophrenia. U.S. Patent No. 5447948. September 5, 1995; (ii) Vladimir C, Krystal JH, Sanacora G. Glutamate Modulating Agents in the Treatment of Mental Disorders. U.S. Patent No. 8778979 B2. Patent Issue Date July 15, 2014. U.S. Patent Application No. 15/695,164. Filing Date September 5, 2017; (iii) Charney D, Krystal JH, Manji H, Matthew S, Zarate C. Intranasal Administration of Ketamine to Treat Depression. U.S. Patent Application No. 14/197767 filed on March 5, 2014. U.S. Application or Patent Cooperation Treaty International Application No. 14/306382 filed on June 17, 2014; (iv) Zarate C, Charney DS, Manji HK, Mathew SJ, Krystal JH, Department of Veterans Affairs. Methods for Treating Suicidal Ideation. Patent Application No. 14/197767 filed on March 5, 2014, by Yale University Office of Cooperative Research; (v) Arias A, Petrakis I, Krystal JH. Composition and Methods to Treat Addiction. Provisional Use Patent Application No. 61/973/961. April 2, 2014. Filed by Yale University Office of Cooperative Research; (vi) Chekroud A, Gueorguieva R, Krystal JH. Treatment Selection for Major Depressive Disorder. U.S. Patent and Trademark Office Docket No. Y0087.70116US00. Filed June 3, 2016. Provisional patent submission by Yale University; (vii) Gihyun Y, Petrakis I, Krystal JH. Compounds, Compositions, and Methods for Treating or Preventing Depression and Other Diseases. U.S. Provisional Patent Application No. 62/444552. Filed on January 10, 2017 by Yale University Office of Cooperative Research OCR 7088 US01; (viii) Abdallah C, Krystal JH, Duman R, Sanacora G. Combination Therapy for Treating or Preventing Depression or Other Mood Diseases. U.S. Provisional Patent Application No. 62/719935. Filed on August 20, 2018, by Yale University Office of Cooperative Research OCR 7451 US01. AstraZeneca Pharmaceuticals provides the drug saracatinib for research related to JHK’s work supported by the National Institute on Alcohol Abuse and Alcoholism grant Center for Translational Neuroscience of Alcoholism (CTNA-4). The other authors have nothing to disclose. SVA, SLF, JMF, and DHM are United States Government employees. The Department of Veterans Affairs had no role in the study design, collection, analysis, interpretation of the data, writing the manuscript, or the decision to submit the paper for publication. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government.